Tralokinumab (Adbry, Leo Pharma) Shows Efficacy and Safety in Moderate-to-Severe Hand AD
Tralokinumab (Adbry/Adtralza, LEO Pharma) met the primary and all key secondary endpoints in an interim analysis of a Phase 3b study of adults with moderate-to-severe atopic dermatitis (AD), the Company reports. ADHAND is a Phase 3b clinical trial that evaluated the efficacy and safety of tralokinumab 300mg administered every two weeks as a monotherapy compared […]